CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...